{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:31:36Z","timestamp":1787167896289,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical lesions of sarcomatoid carcinoma are very rare, and there are still no reports of any targeted drugs applied in this rare tumor. In this report, we document a patient with stage IVA sarcomatoid carcinoma of the cervix, according to the FIGO staging system. The genetic testing of the patient\u2019s tumor tissue indicated the expression of PD-L1. This finding is significant as it suggests that the patient may be a candidate for immunotherapy. In this manuscript, we report a case of a patient who achieved a transient recurrence-free survival period through combined therapy (although recurrence eventually occurred), with a progression-free survival exceeding 13 months and an overall survival exceeding 22 months (as of the last follow-up, the patient was receiving palliative care only).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>After diagnostic confirmation, the patient was administered a first-line combination therapy consisting of pembrolizumab plus bevacizumab. After 2 cycles of treatment, there was a marked reduction in tumor volume and the patient did not experience any side effects. Since then, the patient has continued to receive the regimen and the tumor has continued to shrink. Ultimately, after 10 courses of treatment with immune checkpoint inhibitors and anti-angiogenic drugs, the PET-CT scan showed complete disappearance of the tumor, with no evidence of cancer throughout the body. Subsequently, the patient continued to receive maintenance therapy with the same regimen, with regular follow-up evaluations. No recurrence was detected until 13 months later, when a MRI scan revealed tumor recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of a PD-1 inhibitor with a drug that promotes tumor vascular normalization has shown promise in treating advanced cervical sarcomatoid carcinoma. We are the first to report the use of this combination regimen in this rare tumor, where previously reported treatment has been with chemotherapy agents. In addition, the level of PD-L1 expression could serve as a potential biomarker to predict the response to immunotherapy in patients with advanced sarcomatoid carcinoma of the cervix. Our case highlights the efficacy of immunotherapy in combination with anti-angiogenic targeted therapy for the treatment of sarcomatoid carcinoma of the cervix.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1586531","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T04:14:37Z","timestamp":1757304877000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Outstanding treatment success of pembrolizumab and bevacizumab combination therapy in first-line treatment of cervical sarcomatoid carcinoma: a rare case report"],"prefix":"10.3389","volume":"15","author":[{"given":"Mingzi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinbei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/0973-1482.39604","article-title":"Sarcomatoid squamous cell carcinoma of uterine cervix: pathology, imaging, and treatment","volume":"4","author":"Kumar","year":"2008","journal-title":"J Cancer Res Ther"},{"key":"B2","article-title":"Sarcomatoid squamous cell carcinoma of the uterine cervix: case report","volume":"21","author":"Rodrigues","year":"2000","journal-title":"Eur J Gynaecol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2012.26.5.1110","article-title":"Sarcomatoid carcinoma of the cervix","volume":"32","author":"Nageeti","year":"2012","journal-title":"Ann Saudi Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-010-1409-1","article-title":"Sarcomatoid squamous cell carcinoma of the uterine cervix","volume":"282","author":"Terada","year":"2010","journal-title":"Arch Gynecol Obstet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.gore.2021.100797","article-title":"Cervical carcinoma with histologic components of sarcomatoid carcinoma and multiple basaloid variants: A case report and review of the literature","volume":"37","author":"Haight","year":"2021","journal-title":"Gynecol Oncol Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5264564","DOI":"10.1155\/2017\/5264564","article-title":"Metastatic sarcomatoid squamous cell carcinoma of the cervix presenting with chest mass","volume":"2017","author":"Karapetyan","year":"2017","journal-title":"Case Rep Oncol Med"},{"key":"B7","article-title":"Sarcomatoid squamous cell carcinoma of the uterine cervix successfully treated by laparoscopic radical hysterectomy: a case report","volume":"55","author":"Kong","year":"2010","journal-title":"J Reprod Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12663-018-1119-y","article-title":"Sarcomatoid carcinoma: \u201cA surgeons nightmare","volume":"18","author":"Ramesh","year":"2019","journal-title":"J Maxillofac Oral Surg"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B10","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4103\/0976-7800.127792","article-title":"Sarcomatoid carcinoma of the cervix with foci of Malignant melanoma","volume":"5","author":"Shrivastava","year":"2014","journal-title":"J Midlife Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e53565","DOI":"10.7759\/cureus.53565","article-title":"Sarcomatoid carcinoma: A clinicopathological dichotomy","volume":"16","author":"Ghosal","year":"2024","journal-title":"Cureus"},{"key":"B13","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-22-2192","article-title":"Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study","volume":"12","author":"Xiang","year":"2023","journal-title":"Transl Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"431402049","DOI":"10.1177\/1758835920950207","article-title":"Pulmonary sarcomatoid carcinoma: progress, treatment and expectations","volume":"12","author":"Li","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16142541","article-title":"Management for cervical cancer patients: A comparison of the guidelines from the international scientific societies (ESGO-NCCN-ASCO-AIOM-FIGO-BGCS-SEOM-ESMO-JSGO)","volume":"16","author":"Restaino","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1586531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T04:14:38Z","timestamp":1757304878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1586531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":23,"alternative-id":["10.3389\/fonc.2025.1586531"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1586531","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"article-number":"1586531"}}